New drug targets Hard-to-Treat cancers in early trial
NCT ID NCT04617314
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a new drug called RC108-ADC in 67 people with advanced solid tumors that have a specific protein (c-Met). The drug is designed to deliver a toxin directly to cancer cells. The main goals were to check safety and find the best dose. Researchers also looked at whether tumors shrank or growth slowed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RC108-ADC (an antibody-drug conjugate targeting c-Met protein)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors that have a specific protein called c-Met.
What could go wrong
This is an early Phase 1 trial with only 67 participants, so it is primarily testing safety. The drug may not shrink tumors or improve survival, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, China
-
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College
Beijing, Beijing Municipality, 100021, China
-
The First Hospital of Jilin University
Changchun, Jilin, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China